What is William Blair’s Estimate for ResMed FY2025 Earnings?

ResMed Inc. (NYSE:RMD) – William Blair lifted their FY2025 earnings estimates for ResMed in a research report issued to clients and investors on Monday, February 3rd. William Blair analyst M. Andrew now expects that the medical equipment provider will earn $9.40 per share for the year, up from their previous forecast of $9.30. The consensus estimate for ResMed’s current full-year earnings is $9.41 per share. William Blair also issued estimates for ResMed’s Q1 2026 earnings at $2.66 EPS, Q2 2026 earnings at $2.80 EPS, Q3 2026 earnings at $2.55 EPS and Q4 2026 earnings at $2.67 EPS.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%.

Other equities analysts have also issued research reports about the stock. Piper Sandler upped their price target on shares of ResMed from $252.00 to $260.00 and gave the stock a “neutral” rating in a research report on Friday, January 31st. StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. UBS Group upgraded ResMed from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 31st. Royal Bank of Canada increased their price objective on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a report on Friday, October 25th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a research note on Friday, January 31st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, ResMed currently has an average rating of “Moderate Buy” and a consensus target price of $244.73.

ResMed Price Performance

Shares of RMD opened at $242.19 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. The company has a market cap of $35.57 billion, a P/E ratio of 28.59, a PEG ratio of 1.69 and a beta of 0.70. ResMed has a 12 month low of $170.56 and a 12 month high of $263.05. The stock has a fifty day moving average price of $239.82 and a 200 day moving average price of $237.15.

Hedge Funds Weigh In On ResMed

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its position in shares of ResMed by 36.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,176 shares of the medical equipment provider’s stock worth $270,000 after purchasing an additional 312 shares in the last quarter. Jacobi Capital Management LLC acquired a new position in ResMed in the 4th quarter valued at approximately $257,000. US Bancorp DE lifted its position in ResMed by 4.1% in the 4th quarter. US Bancorp DE now owns 31,574 shares of the medical equipment provider’s stock worth $7,221,000 after buying an additional 1,254 shares in the last quarter. Fisher Asset Management LLC lifted its position in ResMed by 61.0% in the 4th quarter. Fisher Asset Management LLC now owns 43,028 shares of the medical equipment provider’s stock worth $9,840,000 after buying an additional 16,301 shares in the last quarter. Finally, SVB Wealth LLC acquired a new stake in shares of ResMed during the 4th quarter valued at $257,000. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at ResMed

In other news, insider Justin Leong sold 6,160 shares of ResMed stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $243.09, for a total value of $1,497,434.40. Following the transaction, the insider now directly owns 21,718 shares of the company’s stock, valued at $5,279,428.62. This trade represents a 22.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the sale, the director now owns 77,218 shares of the company’s stock, valued at approximately $18,695,249.98. This trade represents a 2.52 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,094 shares of company stock valued at $2,704,941. Corporate insiders own 0.71% of the company’s stock.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be given a $0.53 dividend. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 annualized dividend and a yield of 0.88%. ResMed’s dividend payout ratio (DPR) is 25.03%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.